Private equity firm Symphony Technology Group has acquired a majority stake in ImpactRx, which provides solutions to pharmaceutical marketing and sales decision makers based on its custom research and analytics. One of ImpactRx's existing investors, Merck Capital Ventures, will retain its minority ownership interest in the company.
